The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012) | Health & Environmental Research Online (HERO)

Health & Environmental Research Online (HERO)

Print Feedback Export to File

This record has one attached file:

Citation
Tags

HERO ID

7684870

Reference Type

Journal Article

Title

The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)

Author(s)

Tutt, A; Cheang, M; Dowsett, M; Fox, L; Gazinska, P; Grigoriadis, A; Gutin, A; Harper-Wynne, C; Hatton, M; Kernaghan, S; Lanchbury, J; Ellis, P; Morden, J; Owen, J; Parikh, J; Parker, P; Rahman, N; Roylance, R; Shaw, A; Smith, Ian; Thompson, R; Timms, K; Kilburn, L; Tovey, H; Wardley, A; Wilson, G; Harries, M; Bliss, J; Gilett, C; Pinder, S; Abraham, J; Barrett, S; Barrett-Lee, P; Chan, S; ,

Year

2015

Is Peer Reviewed?

Yes

Journal

Cancer Research
ISSN: 0008-5472
EISSN: 1538-7445

Publisher

AMER ASSOC CANCER RESEARCH

Location

PHILADELPHIA

Volume

Issue

9_Supplement

Page Numbers

S3-01-S3-01

DOI

10.1158/1538-7445.SABCS14-S3-01

Web of Science Id

WOS:000356730200018

URL

http://cancerres.aacrjournals.org/lookup/doi/10.1158/1538-7445.SABCS14-S3-01
Exit

Conference Name

Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX